A randomized, open-label, single-dosing, 2 ×2 crossover study to compare the safety and pharmacokinetics of HUG116 tablet (tenofovir disoproxil) with Viread tablet (tenofovir disoproxil fumarate) in healthy male subjects.

CONCLUSION: This study found that the PKs of the test formulation (HUG116 tablet; tenofovir disoproxil) and reference formulation (Viread tablet; tenofovir disoproxil fumarate) were similar, and the test formulation met the regulatory criteria for assuming bioequivalence with the reference formulation. PMID: 32990214 [PubMed - as supplied by publisher]
Source: International Journal of Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research